Search
9 studies match these filters. Showing 1–9 of 9 studies
| Registration number | Study | Status | Phase | Enrolment | Sites / countries | Start year | Last updated | Actions |
|---|---|---|---|---|---|---|---|---|
| NCT06423911 | Study of Olverembatinib (HQP1351) in Patients With CML-CP Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T315I mutation (Part B). Patients who meet ELN 2025 failure c… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 163 sites in total | Recruiting | Phase 3 | 333target | 163 / 16 | 2024 | Sep 15, 2026 | |
| NCT07213778 | REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 36 sites in total | Recruiting | Phase 3 | 2,000target | 36 / 4 | 2025 | Sep 14, 2026 | |
| NCT07764978 | Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnos… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 124 sites in total | Recruiting | Phase 3 | 750target | 124 / 15 | 2026 | Aug 14, 2026 | |
| NCT07321652 | Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhib… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 210 sites in total · contact listed | Recruiting | Phase 3 | 466target | 210 / 1 | 2026 | Sep 2, 2026 | |
| NCT04566328 | Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell g… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 647 sites in total | Recruiting | Phase 3 | 1,450target | 647 / 2 | 2021 | Aug 19, 2026 | |
| NCT03150693 | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy dr… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 460 sites in total · contact listed | Recruiting | Phase 3 | 303target | 460 / 2 | 2017 | Sep 2, 2026 | |
| NCT03959085 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab ozogamicin is a monoclonal antibody, which is a type of protei… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 231 sites in total · contact listed | Recruiting | Phase 3 | 5,951target | 231 / 5 | 2019 | Aug 25, 2026 | |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 279 sites in total · contact listed | Recruiting | 75,000target | 279 / 6 | 2015 | Aug 25, 2026 | ||
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 745 sites in total · contact listed | Recruiting | 2,000target | 745 / 1 | 2022 | Sep 2, 2026 |